Bacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number:

Similar documents
Interpretation At-a-Glance

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21

Mark Your Calendars Now! Next Event Ships: September 14, 2015

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

Concise Antibiogram Toolkit Background

General Approach to Infectious Diseases

CONTAGIOUS COMMENTS Department of Epidemiology

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Author - Dr. Josie Traub-Dargatz

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Terry Talks Nutrition: Infectious microbes

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Antibiotic Protocol. What to do if you must use an antibiotic

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

Can levaquin treat group b strep

CONTAGIOUS COMMENTS Department of Epidemiology

Lecture 6: Fungi, antibiotics and bacterial infections. Outline Eukaryotes and Prokaryotes Viruses Bacteria Antibiotics Antibiotic resistance

Xochitl Morgan: The human microbiome; the role of commensals in health and disease.

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Classification of Bacteria

Recurrent Bacterial Vaginosis

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

Finnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs

Burn Infection & Laboratory Diagnosis

Hompes Method. Practitioner Training Level II. Lesson Six Part B - Functional Stool Tests

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

Antibiotic stewardship in long term care

microbiology testing services

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

Fungal Disease. What is a fungus?

Chapter 9: Antiinfective Medications Edmunds: Introduction to Clinical Pharmacology, 8th Edition

For all species and ages. Related Products :

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

CONTAGIOUS COMMENTS Department of Epidemiology

Understanding the Hospital Antibiogram

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

Using SCC to Evaluate Subclinical Mastitis Cows

UNDERSTANDING THE ANTIBIOGRAM

2016 Antibiotic Susceptibility Report

Summary of the latest data on antibiotic resistance in the European Union

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

MICRO-ORGANISMS by COMPANY PROFILE

Antibiotic Resistance The Global Perspective

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

Mastitis: Background, Management and Control

AVIAN PROBIOTIC AVI-CULTURE-2 REDUCES NEONATAL MORTALITY AND HELPS TO IMPROVE BREEDING PERFORMANCE DGTDVM-2012 by Dr Gianluca Todisco, DVM, PhD Italy

What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown

Cost high. acceptable. worst. best. acceptable. Cost low

The Nuts and Bolts of Antibiograms in Long-Term Care Facilities

Controlling Bacterial Growth

Cipro for gram positive cocci in urine

SPECIMEN COLLECTION FOR CULTURE OF BACTERIAL PATHOLOGENS QUICK REFERENCE

MASTITIS DNA SCREENING

Application of sewage in pisciculture in order to augment fish production has been an

VPM 201: Veterinary Bacteriology and Mycology 26-27/10/2011. LABORATORY 8a - URINARY TRACT INFECTIONS (UTIs)

Group b strep and macrodantin

Natural Language Processing for Public Health

Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus

THE HUMAN MICROBIOME: THE INFECTION PREVENTIONIST S BEST FRIEND

Can i take diflucan with antibiotics

Inhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani

3.0 Treatment of Infection

Can fluconazole treat c diff

Role of the nurse in diagnosing infection: The right sample, every time

AGISAR Pilot Project on Integrated Surveillance of AMR in Uganda

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme

Running head: CLOSTRIDIUM DIFFICILE 1

Project Summary. Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data

Should we test Clostridium difficile for antimicrobial resistance? by author

Pharm 262: Antibiotics. 1 Pharmaceutical Microbiology II DR. C. AGYARE

Multi-Drug Resistant Organisms (MDRO)

2015 Antibiotic Susceptibility Report

Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method.

Exclusion zone for harmful bacteria! Aviguard FOR BROILERS, LAYERS, TURKEYS AND GAMEBIRDS

Medical Microbiology Syllabus MBIO 4300 Lecture: 1:00-1:50 PM, M-W-F Lab: 2:00 4:50 PM, M Room: Naraghi Hall, 331 Fall 2016

The South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa

DO NOT WRITE ON or THROW AWAY THIS PAPER!

Intrinsic, implied and default resistance

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

Microbiology ( Bacteriology) sheet # 7

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Antibiotic Resistance

Background and Plan of Analysis

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013

Transcription:

Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, urrey. KT3 6NB Bacteriology Lactobacillus species 3+ Escherichia coli 4+ Bifidobacterium 3+ gamma haemolytic treptococcus NP 4+ alpha haemolytic treptococcus NP 3+ Haemolytic Escherichia coli NP 4+ erratia marcescens PP 4+ Klebsiella pneumoniae NP 3+ Mycology Candida albicans NP 1+ Candida parapsilosis NP 1+ Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathological significance should be based upon clinical symptoms and reproducibility of bacterial recovery. *NG NP PP P *NG Lab Comments ENI': All yeast, add'l bacteria Please note that Genova Diagnostics recently upgraded the automated bacterial identification and susceptibility system to the Vitek 2 system to provide faster and definitive identification of bacteria. As a result the following minor changes to antibiotic sensitivities reported for specific bacteria will be effective July 2007: taphylococcus aureus susceptibility reports will no longer include Erythromycin. treptococcus agalactiae susceptibility reports will no longer report Cefazolin (an I.V./I.M. antibiotic), Genova Diagnostics CLIA Lic. #34D0655571 Medicare Lic. #34-8475

ID: 93201234 Page 2 Nitrofurantoin (not a drug of choice for the sites tested), or Erythromycin. Commentary is provided to the practitioner for educational purposes, and should not be interpreted as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the responsibility of the practitioner. Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathological significance should be based upon clinical symptoms and reproducibility of bacterial recovery. ufficient amounts of Lactobacilli and E. coli appear to be present in the stool. Ample amounts of E. coli have been associated with a balanced gut flora. The "friendly bacteria", Lactobacilli and Bifidobacteria, are important for gastrointestinal function, as they are involved in vitamin synthesis, natural antibiotic production, immune defense, digestion, detoxification of pro-carcinogens and a host of other activities. upplementation with Lactobacilli might be considered in selected cases where the organisms are in the low range of normal. Bifidobacteria is below optimal levels. Ideally, levels of Lactobacillus and E. coli should be 2+ or greater. Bifidobacteria being a predominate anaerobe should be recovered at levels of 4+. A 1+ quantity of yeast is considered an acceptable amount of yeast in the stool. It may, however, reflect a condition of yeast overgrowth, especially when moderate or many yeast are reported on the microscopic (parasitology) exam, or may lead to symptoms in individuals showing deficient beneficial bacteria. Genova Diagnostics CLIA Lic. #34D0655571 Medicare Lic. #34-8475

Prescriptive Agents ERRATIA MARCECEN I R Amox./Clavulanic Acid R Ampicillin R Cephalothin R Ciprofloxacin Tetracycline Trimethoprim/ulfa Indicates susceptibility to prescriptive agents I Indicates intermediate susceptibility to prescriptive agents R Indicates resistance to prescriptive agents Natural Agents ERRATIA MARCECEN Berberine Oregano Plant Tannins Uva-Ursi Prescriptive Agents: Microbial testing has been performed in vitro to determine antibiotic sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antibiotics that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antibiotics that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antibiotics that appear in the "R" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antibacterials often results in the emergence of resistance. Natural Agents: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro envrionment. High inhibition indicates a greater ability by the natural substance to limit growth, while a lesser ability to limit growth. These natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances. usceptibility to tetracycline is predictive for susceptibility to minocycline, however in vitro resistance to tetracycline may or may not accurately predict resistance to minocycline. Call the Medical Director if consultation is required. This test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared or approved by the U.. Food and Drug Administration. 63 Zillicoa treet Asheville, NC 28801-1074 Genova Diagnostics - College of American Pathologists #31722-01 CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

Prescriptive Agents KLEBIELLA PNEUMONIAE I R Amox./Clavulanic Acid Ampicillin R Cephalothin Ciprofloxacin Tetracycline Trimethoprim/ulfa Indicates susceptibility to prescriptive agents I Indicates intermediate susceptibility to prescriptive agents R Indicates resistance to prescriptive agents Natural Agents KLEBIELLA PNEUMONIAE Berberine Oregano Plant Tannins Uva-Ursi Prescriptive Agents: Microbial testing has been performed in vitro to determine antibiotic sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antibiotics that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antibiotics that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antibiotics that appear in the "R" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antibacterials often results in the emergence of resistance. Natural Agents: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro envrionment. High inhibition indicates a greater ability by the natural substance to limit growth, while a lesser ability to limit growth. These natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances. usceptibility to tetracycline is predictive for susceptibility to minocycline, however in vitro resistance to tetracycline may or may not accurately predict resistance to minocycline. Call the Medical Director if consultation is required. This test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared or approved by the U.. Food and Drug Administration. 63 Zillicoa treet Asheville, NC 28801-1074 Genova Diagnostics - College of American Pathologists #31722-01 CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

CANDIDA ALBICAN Azole Antifungals I R Fluconazole <=0.125 Itraconazole =0.125 Ketoconazole =0.125 Indicates susceptibility to prescriptive agents I Indicates intermediate susceptibility to prescriptive agents R Indicates resistance to prescriptive agents Non-absorbed Antifungals Azole Antifungals: Microbial testing has been performed in vitro to determine antifungal sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antifungals that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antifungals that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antifungals that appear in the "R" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antifungals often results in the emergence of resistance. CANDIDA ALBICAN Nystatin Natural Antifungals CANDIDA ALBICAN Berberine Caprylic Acid Garlic Undecylenic Acid Plant tannins Uva-Ursi Nystatin and Natural Antifungals: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro environment. High Inhibition indicates a greater ability by the natural substance to limit growth, while Low Inhibition a lesser ability to limit growth. In accordance with laboratory guidelines for reporting sensitivities, results for Nystatin are now being reported with natural antifungals in this category. This test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared or approved by the U.. Food and Drug Administration. 63 Zillicoa treet Asheville, NC 28801-1074 Genova Diagnostics - College of American Pathologists #31722-01 CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

CANDIDA PARAPILOI Azole Antifungals I R Fluconazole =1.0 Itraconazole =0.5 Ketoconazole =0.25 Indicates susceptibility to prescriptive agents I Indicates intermediate susceptibility to prescriptive agents R Indicates resistance to prescriptive agents Non-absorbed Antifungals Azole Antifungals: Microbial testing has been performed in vitro to determine antifungal sensitivity and resistance at standard dosages. Prudent use of antimicrobials requires knowledge of appropriate blood or tissue levels of those agents. Antifungals that appear in the "" (susceptible) column are more effective at inhibiting the growth of this organism. Antifungals that appear in the "I" (intermediate) column are partially effective at inhibiting the growth of this organism. Antifungals that appear in the "R" (resistant) column allow continued growth of the organism in vitro and are usually less effective clinically. Inappropriate use of antifungals often results in the emergence of resistance. CANDIDA PARAPILOI Nystatin Natural Antifungals CANDIDA PARAPILOI Berberine Caprylic Acid Garlic Undecylenic Acid Plant tannins Uva-Ursi Nystatin and Natural Antifungals: In this assay, "inhibition" is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the natural substance was at limiting the growth of an organism in an in vitro environment. High Inhibition indicates a greater ability by the natural substance to limit growth, while Low Inhibition a lesser ability to limit growth. In accordance with laboratory guidelines for reporting sensitivities, results for Nystatin are now being reported with natural antifungals in this category. This test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared or approved by the U.. Food and Drug Administration. 63 Zillicoa treet Asheville, NC 28801-1074 Genova Diagnostics - College of American Pathologists #31722-01 CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, urrey. KT3 6NB Methodologies used for the Ova & Parasites examination are sedimentation concentration of specimens followed by analysis by iodine wet mount and Trichrome stain permanent smear. Dientamoeba fragilis: Many Trophozoites tool Representative photograph of organism(s) Dientamoeba fragilis trophozoites Genova Diagnostics CLIA Lic. #34D0655571 Medicare Lic. #34-8475

ID: 93201234 Page 2 Lab Comments ENI': All yeast, add'l bacteria Commentary is provided to the practitioner for educational purposes, and should not be interpreted as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the responsibility of the practitioner. Dientamoeba fragilis is a pathogenic flagellate. Transmission is by direct ingestion of the trophozoite, via contaminated water. The organism usually resides in the cecum and proximal colon. ymptoms may include diarrhea, abdominal tenderness, weight loss, fatigue, blood in the stool and eosinophilia, although asymptomatic infections can occur. Genova Diagnostics CLIA Lic. #34D0655571 Medicare Lic. #34-8475